Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.32 USD
0.00 (1.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.32 USD
0.00 (1.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
New Strong Sell Stocks for August 12th
by Zacks Equity Research
WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021
Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)
by Zacks Equity Research
Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.